Capricor's Duchenne vote is a verdict on design choices made years before the data
An FDA panel voted against deramiocel on a secondary cardiac endpoint measured partly in boys whose hearts were still stable. The agency then pointed the sponsor back to its primary endpoint.
Reality
- Evidence38
- Adoption15